Rimonabant developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as 'the munchies'. Acomplia works on the premise that if cannabinoids stimulate appetite, blocking cannabinoid receptors in the brain might reduce appetite.
The central cannabinoid (CB1) receptors are believed to play a role in controlling food consumption and the phenomena of dependence or habit. Acomplia (Rimonabant) emerged from this researched process as a potent CB1 receptor antagonist. Preclinical animal studies subsequently showed that it could reduce consumption of fats and sugars, which contribute to weight gain.
Trials involving over 6,000 obese subjects that were carried out in both the US and Europe, showed that overweight and obese patients taking Acomplia (Rimonabant) achieved significant reductions in body weight, and waist circumference (an indicator of abdominal obesity).
We feel in the prevailing market there is a clear opportunity for an effective and well-tolerated anti-obesity drug.
The US FDA has yet to vote to approve this drug in the US. The vote on this medication in Europe is expected at the end of June 2007.
BLU Electronic Cigarettes
Blu gives you much much more!
About Me
- Online Village Cafe for BLU
- We at Online Village Cafe understand how difficult it can be to find what you are looking for in the ever changing world of shopping. We are here to review popular items on the market today and give our opinions, coupons, advice on products we purchase, try, and then comment on for you. Sometimes reading others opinions before you buy is the best way to test a product without taking on the expense yourself. We also post a great deal of health articles for you to read! So be sure to stop in often and see what we have reviewed lately or what new health article we have posted!
